Abstract: A method and apparatus for normalizing data. A computer system receives category data for a first code from a first client of a plurality of clients. The computer system also generates a category rule based on the category data. The computer system also assigns a category to a second code of a second client of the plurality of clients using the category rule. The category data is generated using input from the first client. Assigning the category to the second code of the second client comprises selecting the category rule to use to assign the category to the second code from a plurality of category rules.

Abstract: Oxepan-2-yl pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: A method and system for analyzing employee retention across an enterprise based on commuter modeling is disclosed. The method can be implemented in a computer system which includes: mapping longitudinal and latitudinal coordinates of address information of a plurality of employees and a work location onto a map, which shows a predefined geographic location encompassing the work location surrounded by the longitudinal and latitudinal coordinates of the address information; obtaining calculated analytics data of employee turnover rate for the plurality of employees based on a commute distance from the work location to each of the longitudinal and latitudinal coordinates of the plurality of employees; and graphically overlaying the analytics data of the turnover rate for the plurality of employees onto the map to show employee turnover rate for different segments of the map.

Abstract: Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: 5-Azaindazole compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: A medical image processing apparatus according to an embodiment includes processing circuitry. The processing circuitry implements registration on a medical image and each of a plurality of reference images. The processing circuitry performs deformation on the medical image based on a result of the registration. The processing circuitry sets a first region of interest on the deformed medical image. The processing circuitry sets on at least two of the plurality of reference images, a second region of interest corresponding to the first region of interest. The processing circuitry retrieves from the reference images on which the second region of interest is set, a reference image similar to an image in the first region of interest.

Abstract: Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Described herein are compounds that are estrogen receptor modulators of Formula I: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: A method, executed by a processor, for estimating media metrics from large population data includes formatting and storing panel data, the panel data comprising observed viewing data of a plurality of individual panelists and demographic data for the plurality of panelists, the panel being drawn from a large population; accessing the large population data, the large population data comprising household-level viewing data and household level demographics; training a model to estimate viewing audience size based on the observed panel data; estimating, using the trained model, audience size for each household in the large population data; estimating a viewing score for each individual viewer in a plurality of households in the large population data; and combining the estimates of audience size and viewing score to produce probabilities that each of the viewers in the household viewed a specific media event.

Abstract: In response to a data input of a title text string that indicates a title of a person for a job within an organization, title scores are generated for predefined titles in proportion to strength of match to the title text string. A predefined title having the highest title score is selected as a matching title for the title text string input. A person score is generated from the title score of the matching title as a function of other title scores of the predefined titles matched to the person. An organization score is generated as a function of the person score and an occurrence frequency of the matching title associated with the organization. Classification of the matching title within a classification database is updated as a function of one or more of the organization score, the title score and the person score.

Abstract: Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Pyridone and pyrazinone compounds of Formula I including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Pyridazinone compounds of Formula I including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: An image processing apparatus according to an embodiment includes a scanning protocol creation unit, an image acquisition unit, a post-processing unit, and a storage unit. The scanning protocol creation unit creates a scanning protocol for a particular part of body of an object. The image acquisition unit acquires source image data by scanning the particular part using an imaging device according to scanning parameters in the scanning protocol. The post-processing unit performs post-processing on the source image data according to post-processing parameters in the scanning protocol to obtain processed image data. The storage unit stores the scanning protocol, or store the source image data and the processed image data or index identifiers thereof in association with parameters related to the scanning protocol as single job data of the object. The scanning protocol includes the scanning and the post-processing parameters, and information related to the imaging device and the post-processing unit.